long-term effects of treatment in patients previously treated for childhood hodgkin's lymphoma

Conditions: Long-term Effects Secondary to Cancer Therapy in Children; Lymphoma

Summary: rationale: assessing the long-term effects of cancer treatment in cancer survivors may help improve the ability to plan effective treatment and follow-up care. purpose: this clinical trial is studying the long-term effects of treatment in patients who were previously treated for childhood hodgkin's lymphoma.

objectives: * determine the cumulative incidence and characterize the spectrum of selected adverse physiologic and psychosocial outcomes, using self-report and clinical evaluation, in patients previously treated for childhood hodgkin's lymphoma. * compare the cumulative incidence and spectrum of self-reported adverse outcomes of these patients, using data collected at a comparable time period after diagnosis, with hodgkin's lymphoma survivors from the childhood cancer survivor study (ccss). * compare self-reported health-related outcomes with outcomes detected by clinical evaluation and medical record review of each group of patients. outline: this is a cohort, cross-sectional, multicenter study. * contemporary group: patients complete a self-report of long-term outcomes questionnaire and a comprehensive psychosocial questionnaire. a medical record review is then performed. patients then undergo a comprehensive risk-based clinical evaluation with specific examinations and studies based upon the children's oncology group late effects screening guidelines and the patients' specific therapeutic exposures. * childhood cancer survivor study (ccss) group: patients undergo a telephone interview and have medical records reviewed to validate select self-reported long-term outcomes. patient replies from the baseline ccss questionnaire (which was completed at certain timepoints after diagnosis) are reviewed for targeted long-term outcomes. projected accrual: approximately 1,000 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * contemporary cohort * at least 5 years since diagnosis of hodgkin's lymphoma * diagnosed between the years 1987-2001 * 21 and under at diagnosis * no evidence of disease * prior treatment on 1 of the following protocols during the years 1987-2001: * children's cancer group (ccg) ccg-5942, ccg-59704 * pediatric oncology group (pog) pog-8625, pog-8725, pog-9425, pog-9426 * pediatric hodgkin's consortium: vamp, vepa, vamp/cop * institutional protocols copp/abv, mopp/abvd, abvd * childhood cancer survivor study (ccss) hodgkin's lymphoma cohort * current enrollment in the ccss * diagnosed between the years 1976-1986 * completed baseline questionnaire at comparable timepoints (as the contemporary cohort) after diagnosis patient characteristics: age * any age performance status * not specified life expectancy * not specified hematopoietic * not specified hepatic * not specified renal * not specified prior concurrent therapy: biologic therapy * not specified chemotherapy * not specified endocrine therapy * not specified radiotherapy * not specified surgery * not specified

Keywords: long-term effects secondary to cancer therapy in children stage i childhood hodgkin lymphoma stage ii childhood hodgkin lymphoma stage iii childhood hodgkin lymphoma stage iv childhood hodgkin lymphoma